Outlook Therapeutics (OTLK) Enterprise Value (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Enterprise Value of -$7.7 million for Q1 2026, down 2.54% year-over-year from -$8.0 million in Q1 2025, and up 10.71% quarter-over-quarter from -$8.7 million in Q4 2025.
Outlook Therapeutics (OTLK) Enterprise Value (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Enterprise Value for 12 consecutive years, with -$7.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 2.54% year-over-year to -$7.7 million; the TTM figure through Mar 2026 stood at -$7.7 million (down 2.54% YoY), while the FY2025 annual figure was -$8.1 million, up 45.85% from the prior year.
- Enterprise Value rose to -$7.7 million in Q1 2026 per OTLK's latest filing, from -$8.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$5.7 million in Q4 2024 and bottomed at -$58.4 million in Q1 2022.
- Historically, Enterprise Value has averaged -$23.9 million across 5 years, with a median of -$17.4 million in 2022.
- Annual changes were most pronounced in 2022 — Enterprise Value tumbled 57.19% — and 2025, when it soared 84.0%.
- Outlook Therapeutics' Enterprise Value stood at -$52.3 million in 2022, then soared by 80.21% to -$10.4 million in 2023, then jumped by 44.94% to -$5.7 million in 2024, then tumbled by 52.17% to -$8.7 million in 2025, then gained by 10.71% to -$7.7 million in 2026.
- Business Quant data shows OTLK's Enterprise Value at -$7.7 million in Q1 2026, -$8.7 million in Q4 2025, and -$8.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Outlook Therapeutics | 93.64 Mn | 82.40 Mn | -8,265.00 | -11.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.75 Mn |
| Dec 31, 2025 | -8.68 Mn |
| Sep 30, 2025 | -8.08 Mn |
| Jun 30, 2025 | -8.90 Mn |
| Mar 31, 2025 | -7.56 Mn |
| Dec 31, 2024 | -5.70 Mn |
| Sep 30, 2024 | -14.93 Mn |
| Jun 30, 2024 | -32.02 Mn |
| Mar 31, 2024 | -47.23 Mn |
| Dec 31, 2023 | -10.36 Mn |
| Sep 30, 2023 | -23.39 Mn |
| Jun 30, 2023 | -33.71 Mn |
| Mar 31, 2023 | -43.63 Mn |
| Dec 31, 2022 | -52.34 Mn |
| Sep 30, 2022 | -17.40 Mn |
| Jun 30, 2022 | -26.02 Mn |
| Mar 31, 2022 | -58.42 Mn |
| Dec 31, 2021 | -70.15 Mn |
| Sep 30, 2021 | -14.48 Mn |
| Jun 30, 2021 | -19.69 Mn |